illumina

RET

CANCERTAINTY OF CANCER TO THE PRECISION OF PROFILE

тмв 🥕

KHAS

BIOMARKERS SINGLE INSIGHT

Illumina platforms have been adopted by oncology institutions worldwide, with over 90% of the world's sequencing data generated using Illumina sequencing by synthesis (SBS) technology.¹

From library preparation to sequencing to data analysis, Illumina next-generation sequencing (NGS) solutions are effective and efficient methods for obtaining deep and accurate insights, helping power significant advancements in oncology research.

Consolidate biomarker evaluation

Analyze multiple biomarkers in a single NGS assay to increase the chances of finding a relevant genomic alteration in a sample

Obtain accurate results

Take advantage of high-quality assays, proven sequencing technology, and sophisticated data analysis algorithms and solutions

Uncover key variant categories and biomarker signatures

Identify DNA variants, RNA variants, tumor mutational burden (TMB), and microsatellite instability (MSI) from solid tumor or blood samples



RESOLUTION ACROSS THE ONCOLOGY SPECTRUM

Every tumor is unique. Illumina NGS solutions can help you find the right approach, from single gene to comprehensive analysis, and go from uncertainty to insight.

HEREDITARY CANCER RISK ASSESSMENT

Identify predisposing cancer mutations, from single nucleotide polymorphisms (SNPs) and indels to CNVs, in one or multiple genes.

TruSight[™] Hereditary Cancer Panel AmpliSeq[™] for Illumina *BRCA* Panel

FOCUSED SOLID TUMOR PROFILING

Narrow your focus with simple and fast multivariant discovery optimized to use as little as 1 ng of highquality DNA.

TruSight Tumor 15 AmpliSeq for Illumina HotSpot Panel AmpliSeq for Illumina Focus Panel

HEMATOLOGY INSIGHTS

Consolidate iterative tests into a multimarker, singleassay approach with the power to detect different variants, including known SNVs, difficult GC regions, CNVs, and novel fusions.

TruSight Myeloid Sequencing Panel TruSight RNA Fusion Panel AmpliSeq for Illumina Myeloid Panel

ENABLING COMPREHENSIVE GENOMIC PROFILING

Obtain a broader biomarker view and enable comprehensive genomic profiling aligned to key guidelines and clinical trials using both DNA and RNA variants. Incorporate immunotherapy biomarkers like TMB and MSI, increasing the likelihood of finding a relevant biomarker or a clinical trial match.

TruSight Oncology 500 TruSight Oncology 500 ctDNA*† TruSight Oncology 500 High-Throughput†

FLEXIBLE SYSTEMS FOR EVERY LAB

From small laboratories to large core facilities, whether new to NGS or a technology expert, there's an Illumina sequencing system to fit every lab's size, throughput needs, and experience.











iSeq[™] 100 System

MiniSeq™ System

MiSeq[™] Series

NextSeq[™] Series

NovaSeq[™] 6000 System

HIGH-THROUGHPUT

LOW-THROUGHPUT

ADVANCING THE FUTURE OF GENOMICS, TOGETHER

With our state-of-the-art good manufacturing practices (GMP) facility, commitment to International Organization for Standardization (ISO) compliance, and multiple partnerships with pharmaceutical companies to develop IVD companion diagnostics tests, we're helping drive the revolution in cancer genomics.

Learn more about the Illumina oncology portfolio at www.illumina.com/cancergenomics





ENABLING COMPREHENSIVE GENOMIC PROFILING

TruSight Oncology 500 TruSight Oncology 500 ctDNA^{*†} TruSight Oncology 500 High-Throughput[†]

Now you can take advantage of the proven TruSight Oncology 500 assay in three ways:

- Target DNA and RNA variants, plus TMB and MSI status with TruSight Oncology 500 on the NextSeq System
- Analyze circulating tumor DNA (ctDNA) from plasma with TruSight Oncology 500 ctDNA on the NovaSeq System
- Increase tissue sample batching capacity with TruSight Oncology 500 High-Throughput on the NovaSeq System

Powered by NGS, these kits enable you to take advantage of comprehensive genomic profiling and various sample input types. Whichever solution you choose, you'll achieve highly sensitive sequencing results with accurate variant detection on a high-throughput sequencing system.

Reference 1. Data on file. Illumina, Inc. 2018

* Pre-order begins in November 2019 † Under development, coming 2020

For Research Use Only. Not for use in diagnostic procedures.

©2019 Illumina, Inc. All rights reserved. PUB 1176-2018-011 QB 6707



illumina